Patient Profiling
A panel of isogenic cell-lines covering a wide range of human disease genotypes enable drug discovery researchers to determine the optimal patient populations to target with their drug candidates in the expensive clinical trial stage of the drug development process.
Here we ahow proof-of-concept that in vitro isogenic cell-lines do indeed predict responses in humans carrying the same cancer gene.
The availability of such data enables researchers to determine the full range of sensitive and resistant patient populations to the disease target in clinical trials. This will enable the design of smaller more efficient clinical trials that will read-out quicker, be more likely to succeed and reduce the high rate of attrition currently observed at this critical phase of drug development.
Relevant data-sets are available for each application and can be shared under confidential disclosure agreement. Please write to info@horizondiscovery.com for details
Horizon Offering
- Horizon Discovery has a wide range of isogenic models available for immediate licensing or purchasing (Learn more) and; can also develop custom isogenic models or screen drug candidates against your specific gene target (Learn more)
References
- Bardelli, Torrance et al, patent pending, 2008
- Bardelli et al, Cancer Research, March 2007
- Bardelli et al, JCO, November 2008
- Bardelli et al, PNAS, December 2008 (In Press)
- Howes et al, Horizon Discovery, Internal data, October 2008
- Horizon Discovery Ltd. Technical Presentation (Download (6.95MB))